49,252 Shares in AbbVie Inc. $ABBV Bought by NBT Bank N.A.

NBT Bank N.A. purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 49,252 shares of the company’s stock, valued at approximately $12,884,000. AbbVie accounts for approximately 0.9% of NBT Bank N.A.’s holdings, making the stock its 27th largest holding.

A number of other large investors have also added to or reduced their stakes in the stock. Corient Private Wealth LP acquired a new position in AbbVie in the 2nd quarter valued at $559,736,000. Legal & General Group Plc bought a new stake in shares of AbbVie during the 2nd quarter valued at $2,905,952,000. Jupiter Topco LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at $1,560,354,000. Diamant Asset Management Inc. grew its holdings in shares of AbbVie by 21,649.0% during the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock worth $798,456,000 after purchasing an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of AbbVie during the 2nd quarter worth $817,473,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on ABBV shares. Guggenheim restated a “buy” rating and issued a $288.00 price target on shares of AbbVie in a research report on Friday, October 9th. Weiss Ratings raised shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. Canaccord Genuity Group increased their price objective on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and raised their target price for the company from $235.00 to $300.00 in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $279.86.

AbbVie Stock Performance

Shares of ABBV opened at $285.66 on Friday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $291.40. The business’s fifty day moving average is $266.33 and its 200-day moving average is $241.77. The firm has a market cap of $504.70 billion, a price-to-earnings ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the previous year, the firm earned $2.97 EPS. AbbVie’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts forecast that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.